Intelligence Feed event · Equity · 2026-08-27

    Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch

    Question

    Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch

    Direct answer

    Mesoblast published its financial results for the fiscal year ending 2026, registering $120.3 million in total top-line revenue. The performance was anchored by the commercial rollout of RYONCIL, which generated $115.2 million in net sales. The revenue ramp marks a structural milestone for Mesoblast, transitioning the company from clinical development stage to commercial stage product execution. On the clinical pipeline front, Mesoblast finalized patient treatment in the pivotal Phase 3 study for rexlemestrocel-L, positioning the chronic low back pain program for upcoming readout and regulatory engagement.

    Original publisher
    Market Ontology
    Evidence through
    2026-08-27
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch”, revision 1, evidence through 2026-08-27. https://marketontology.com/market-events/2026-08-27/mesoblast-fy2026-revenue-reaches-120-3m-led-by-ryoncil-commercial-launch-70b0ed

    EQUITY
    Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch
    Mesoblast published its financial results for the fiscal year ending 2026, registering $120.3 million in total top-line revenue. The performance was anchored by the commercial rollout of RYONCIL, which generated $115.2 million in net sales. The revenue ramp marks a structural milestone for Mesoblast, transitioning the company from clinical development stage to commercial stage product execution. On the clinical pipeline front, Mesoblast finalized patient treatment in the pivotal Phase 3 study for rexlemestrocel-L, positioning the chronic low back pain program for upcoming readout and regulatory engagement.
    MESO
    Impact
    64
    AUG 27
    SIG
    88%
    MESO
    Mesoblast FY2026 Revenue Reaches $120.3M Led by RYONCIL Commercial Launch
    Mesoblast published its financial results for the fiscal year ending 2026, registering $120.3 million in total top-line revenue. The performance was anchored by the commercial rollout of RYONCIL, which generated $115.2 million in net sales. The revenue ramp marks a structural milestone for Mesoblast, transitioning the company from clinical development stage to commercial stage product execution. On the clinical pipeline front, Mesoblast finalized patient treatment in the pivotal Phase 3 study for rexlemestrocel-L, positioning the chronic low back pain program for upcoming readout and regulatory engagement.
    → Commercial adoption of RYONCIL converts cell therapy clinical approvals into $115.2 million of cash-generative biopharma product revenues for MESO.
    Impact
    Mesoblast published its financial results for the fiscal year ending 2026, registering $120.3 million in total top-line revenue. The performance was anchored by the commercial rollout of RYONCIL, which generated $115.2 million in net sales. The revenue ramp marks a structural milestone for Mesoblast, transitioning the company from clinical development stage to commercial stage product execution. On the clinical pipeline front, Mesoblast finalized patient treatment in the pivotal Phase 3 study for rexlemestrocel-L, positioning the chronic low back pain program for upcoming readout and regulatory engagement.
    Affected
    MESO
    Transmission
    Commercial adoption of RYONCIL converts cell therapy clinical approvals into $115.2 million of cash-generative biopharma product revenues for MESO.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    MESOcommercial cash flow transition and Phase 3 trial completionUp1-4wFull-year revenue reached $120.3M with $115.2M generated by RYONCIL and Phase 3 low back pain dosing completed.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month